Science and Society | Published:

Neurocognitive enhancement: what can we do and what should we do?

Nature Reviews Neuroscience volume 5, pages 421425 (2004) | Download Citation

Subjects

Abstract

Our growing ability to alter brain function can be used to enhance the mental processes of normal individuals as well as to treat mental dysfunction in people who are ill. The prospect of neurocognitive enhancement raises many issues about what is safe, fair and otherwise morally acceptable. This article resulted from a meeting on neurocognitive enhancement that was held by the authors. Our goal is to review the state of the art in neurocognitive enhancement, its attendant social and ethical problems, and the ways in which society can address these problems.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Connecting cortex to machines: recent advances in brain interfaces. Nature Neurosci. (Suppl.) 5, 1085–1088 (2002).

  2. 2.

    & Novel physical treatments for the management of neuropsychiatric disorders. J. Psychosom. Res. 53, 709–719 (2002).

  3. 3.

    & Transcranial Magnetic Stimulation in Neuropsychiatry (American Psychiatric Press, Washington DC, 2000).

  4. 4.

    Better Than Prozac: Creating the Next Generation of Psychiatric Drugs (Oxford Univ. Press, New York, 2003).

  5. 5.

    The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s. Hastings Center Report 26, 12–18 (1996).

  6. 6.

    & Student perceptions of methylphenidate abuse at a public liberal arts college. J. Am. College Health 49, 143–145 (2000).

  7. 7.

    The quest for a smart pill. Sci. Am. 54–65 (September 2003).

  8. 8.

    , & Ginkgo Biloba: a cognitive enhancer? Psychol. Sci. Public Interest 3, 2–11 (2002).

  9. 9.

    Emerging ethical issues in neuroscience. Nature Neurosci. 5, 1123–1129 (2002).

  10. 10.

    & Monitoring and manipulating brain function: new neuroscience technologies and their ethical implications. Hastings Center Report (in the press).

  11. 11.

    'Smart drugs': do they work? Are they ethical? Will they be legal? Nature Rev. Neurosci. 3, 975–979 (2002).

  12. 12.

    Memory enhancement: the search for mechanism-based drugs. Nature Neurosci. 5, 1035–1038 (2002).

  13. 13.

    & The Handbook of Aging and Cognition (Lawrence Erlbaum, Hillsdale, New Jersey, 1992).

  14. 14.

    et al. Donepezil and flight simulator performance: effects on retention of complex skills. Neurology 59, 123–125 (2002).

  15. 15.

    et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol. Psychiatry 15, 189–192 (2002).

  16. 16.

    et al. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci. 20, RC65 (2000).

  17. 17.

    et al. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131, 196–206 (1997).

  18. 18.

    , & Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport 8, 3581–3585 (1997).

  19. 19.

    Off-label uses of modafinil. Am. J. Psychiatry 158, 1341 (2001).

  20. 20.

    et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl.) 165, 260–269 (2003).

  21. 21.

    , & Prevalence of criminal offending by men and women with intellectual disability and the characteristics of offenders. J. Intellect. Disabil. Res. 46, (Suppl.) 6–20 (2002).

  22. 22.

    & Neuropsychiatry of frontal lobe dysfunction in violent and criminal behaviour: a critical review. J. Neurol. Neurosurg. Psychiatry 71, 720–726 (2001).

  23. 23.

    Legislative Commissioners' Office. General Statutes of Connecticut. Title 10, Ch. 169, Sect. 10-212b (1 Jan 2003).

  24. 24.

    United States District Court, New Hampshire, Case No. C-88-412-L (August 1, 1991).

  25. 25.

    Beyond Therapy — Biotechnology and the Pursuit of Happiness (Harper Collins, New York, 2003).

  26. 26.

    Our Posthuman Future (Farrar, Strauss and Giroux, New York, 2002).

  27. 27.

    Cosmetic neurology: the dilemma of altering movement, mood and cognition. Neurology (in the press).

Download references

Acknowledgements

This paper is based, in part, on a meeting held at the New York Academy of Sciences in June 2003, supported by a grant to J.I. from the National Science Foundation with co-sponsorship of a Mushett Family Foundation grant to the Academy. The writing of this paper was supported by NSF and NIH grants to M.J.F. and an NIH grant and a Greenwald Foundation grant to J.I.

Author information

Affiliations

  1. Martha Farah is at the Center for Cognitive Neuroscience, University of Pennsylvania, 3720 Walnut Street, Philadelphia, Pennsylvania 19104, USA

    • Martha J. Farah
  2. Judy Illes is at the Stanford Center for Biomedical Ethics and the Department of Radiology, 701 Welch Road, Stanford, California 94304-5748, USA

    • Judy Illes
  3. Robert Cook-Deegan is at the Center for Genome Ethics, Law and Policy, Institute for Genome Sciences and Policy and Department of Public Policy Studies, Duke University, Room 127C, North Building, Research Drive, Box 90141, Durham, North Carolina 27708-0141, USA

    • Robert Cook-Deegan
  4. Howard Gardner is at the Graduate School of Education, Harvard University, Roy E. Larsen Hall, 2nd Floor, Appian Way, Cambridge, Massachusetts 02138, USA

    • Howard Gardner
  5. Eric Kandel is at the Center for Neurobiology and Behavior, Columbia University and Howard Hughes Medical Institute, 1051 Riverside Drive, New York, New York 10032, USA

    • Eric Kandel
  6. Patricia King is at the Georgetown University Law Center, 600 New Jersey Avenue, NW Washington DC 20001, USA

    • Patricia King
  7. Eric Parens is at the The Hastings Center, 21 Malcolm Gordon Drive, Garrison, New York 10524-5555, USA

    • Eric Parens
  8. Barbara Sahakian is at the Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital (Box 189), Cambridge CB2 2QQ, UK

    • Barbara Sahakian
  9. Paul Root Wolpe is at the Departments of Psychiatry, Medical Ethics, and Sociology, Center for Bioethics, University of Pennsylvania, 3401 Market Street, Philadelphia, Pennsylvania 19104-3319, USA

    • Paul Root Wolpe

Authors

  1. Search for Martha J. Farah in:

  2. Search for Judy Illes in:

  3. Search for Robert Cook-Deegan in:

  4. Search for Howard Gardner in:

  5. Search for Eric Kandel in:

  6. Search for Patricia King in:

  7. Search for Eric Parens in:

  8. Search for Barbara Sahakian in:

  9. Search for Paul Root Wolpe in:

Competing interests

E.K. is a co-founder and Chariman of the scientific board of directors of Memory Pharmaceuticals.

Corresponding authors

Correspondence to Martha J. Farah or Judy Illes.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrn1390

Further reading